抗氧化0维纳米药物克服了AKI抗氧化疗法的障碍
Yuqi Yang1,2, Yayun Nan3, Qiaohui Chen4,5
1Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, 410008, China. qionghuang@csu.edu.cn.
Journal of materials chemistry. B
|August 4, 2023
概括
0-维 (0D) 抗氧化纳米药物通过克服传统疗法的局限性来治疗急性损伤 (AKI) 的前景. 这些纳米药物提供增强的抗氧化特性和改善的脏输送,以有效管理AKI.
科学领域:
- 纳米医学是一种纳米医学.
- 脏生理学 脏生理学
- 抗氧化剂治疗是一种抗氧化疗法.
背景情况:
- 急性损伤 (AKI) 带来了严重的健康风险和经济负担,血液透析是主要治疗方法.
- 目前的抗氧化疗法和纳米酶因药物性能差以及脏障碍而面临挑战.
- 零维 (0D) 纳米药物提供了一种新的方法,因为它们的小尺寸和高性能.
研究的目的:
- 综合审查最近在 0D 纳米药物中为 AKI 抗氧化疗法所取得的进展.
- 在AKI处理中使用的0D纳米材料根据其特性进行分类.
- 分析这些纳米药物的抗氧化机制,体内分布和设计创造力.
主要方法:
- 0D纳米药物的分类为超小金属纳米点,无机非金属量子点和聚合物纳米点.
- 专注于抗氧化机制和代表性研究的体内分布.
- 分析各种OD纳米药物的设计原理和生物相容性.
主要成果:
- 0D纳米药物表现出多抗氧化剂酶模仿活性.
- 这些纳米药物证明了提高淋巴膜过屏障透性的能力.
- 在各种研究中观察到出色的生物相容性和向脏分布.
结论:
- 0D纳米药物代表了AKI抗氧化疗法的有前途的治疗策略.
- 对0D纳米药物的进一步研究可以为设计能吸收药物提供宝贵的见解.
- 这些纳米药物在克服现有AKI治疗的局限性方面提供了独特的优势.
相关概念视频
Electron Transport Chain: Complex I and II
14.5K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
14.5K
Acute Kidney Injury IV: Diagnostic Studies and Prevention
35
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
35
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
Antidotes
685
Antidotes are medicinal substances used to counteract the harmful effects of toxins or drugs in the body. They function in various ways, each uniquely designed to combat specific toxic compounds.
Specific antidotes operate by inhibiting the enzymes that control biochemical pathways, reducing the production of harmful metabolites.
An example of an antidote is atropine, which counteracts the detrimental effects of cholinesterase inhibitors. It achieves this by deactivating muscarinic receptors,...
Specific antidotes operate by inhibiting the enzymes that control biochemical pathways, reducing the production of harmful metabolites.
An example of an antidote is atropine, which counteracts the detrimental effects of cholinesterase inhibitors. It achieves this by deactivating muscarinic receptors,...
685
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Alzheimer's Disease: Treatment
215
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
215


